Abbvie Inc

NYSE:ABBV   3:59:59 PM EDT
-0.86 (-0.74%)
Products, Regulatory

AbbVie Provides Update Regarding RINVOQ

Published: 07/16/2021 13:39 GMT
Abbvie Inc (ABBV) - Abbvie Provides Update Regarding Rinvoq® (upadacitinib) for the Treatment of Moderate to Severe Atopic Dermatitis in the Inc - FDA Did Not Meet Prescription Drug User Fee Act (pdufa) Action Date for Supplemental New Drug Application (snda) for Rinvoq.
Abbvie Inc - No Formal Regulatory Action Has Been Taken on Sndas for Rinvoq in Atopic Dermatitis, Psoriatic Arthritis Or Ankylosing Spondylitis.